{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:55:48Z","timestamp":1793832948656,"version":"4.6.1"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immunotherapy has transformed cancer treatment, but its efficacy remains limited in patients with immunologically \u201ccold\u201d tumors. Triple-negative breast cancer (TNBC), despite elevated PD-L1 expression and high tumor mutation burden, often exhibits poor T cell infiltration, rendering it largely unresponsive to immune checkpoint blockade. Overcoming the immunosuppressive tumor immune microenvironment (TIME) remains a major challenge in oncology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We defined a tumor immune microenvironment gene expression signature (TIME-GES) through transcriptomic analysis of clinical samples. Its performance and relevance were evaluated using representative approaches including enrichment analysis, immune infiltration profiling, receiver operating characteristic analysis, and survival assessment. Based on TIME-GES, we screened 1,865 natural compounds and identified Nitidine Chloride (NCD) as a potential modulator in TNBC.\n                      <jats:italic>In vivo<\/jats:italic>\n                      efficacy of NCD against TNBC was examined by representative assays such as flow cytometry and immunofluorescence. Mechanistic insights into TNBC treatment via TIME-GES were explored through RNA sequencing, quantitative PCR, Western blotting, and cellular thermal shift assay.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      TIME-GES effectively characterizes the tumor immune microenvironment across diverse cancer types. It reliably distinguishes tumor immune phenotypes and predicts patient responses to immunotherapy. Moreover, TIME-GES is strongly associated with survival outcomes in patients receiving immunotherapy and remains a significant prognostic marker for overall survival and mortality in TCGA pan-cancer cohorts, regardless of treatment. Guided by TIME-GES, NCD was identified from a natural product library and shown to modulate TIME-GES gene expression and significantly inhibit TNBC growth\n                      <jats:italic>in vivo<\/jats:italic>\n                      . NCD enhances CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cell\u2013mediated antitumor immunity by upregulating TIME-GES genes and targeting the JAK2-STAT3 signaling pathway, resulting in suppressed tumor growth and reprogramming of the TIME toward a more immunologically active, \u201chot\u201d phenotype.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study identified TIME-GES as a novel biomarker capable of distinguishing tumor immune phenotypes, predicting immunotherapy response, and evaluating prognosis in TNBC. Furthermore, TIME-GES-guided screening led to the discovery of NCD, a promising immunomodulatory agent that reprograms the TIME and enhances anti-tumor immunity in TNBC. This study offers both a robust immune gene signature and a candidate therapeutic to improve immunotherapy outcomes in TNBC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1676768","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T05:17:55Z","timestamp":1762751875000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["A tumor immune microenvironment gene expression signature for predicting prognosis, immunotherapy efficacy, and drug candidates in triple-negative breast cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Li","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingzhou","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengrong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congcong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunjie","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinran","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianya","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1126\/science.342.6165.1432","article-title":"Breakthrough of the year 2013. Cancer immunotherapy","volume":"342","author":"Couzin-Frankel","year":"2013","journal-title":"Sci (N Y NY)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer\u2013immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.canlet.2020.05.035","article-title":"STAT3: a key signaling molecule for converting cold to hot tumors","volume":"489","author":"Hu","year":"2020","journal-title":"Cancer Lett"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1550003","article-title":"Tumor-infiltrating immune cells state-implications for various breast cancer subtypes","volume":"16","author":"Xu","year":"2025","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: a review","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"key":"B7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"Yin","year":"2020","journal-title":"Breast Cancer Res ;: BCR"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2022.2049232","article-title":"Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer","volume":"31","author":"Agostinetto","year":"2022","journal-title":"Expert Opin Investig Drugs"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2020.05.039","article-title":"Efficiently restoring the tumoricidal immunity against resistant Malignancies via an immune nanomodulator","volume":"324","author":"Chen","year":"2020","journal-title":"J Control Release: Off J Control Release Soc"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.16760","article-title":"The subtype-specific molecular function of SPDEF in breast cancer and insights into prognostic significance","volume":"25","author":"Ye","year":"2021","journal-title":"J Cell Mol Med"},{"key":"B11","first-page":"35","article-title":"Oncogenes, tumour suppressor genes and growth factors in breast cancer: novel targets for diagnosis, prognosis and therapy","volume":"18","author":"Callahan","year":"1993","journal-title":"Cancer Surv"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/415530a","article-title":"Gene expression profiling predicts clinical outcome of breast cancer","volume":"415","author":"van \u2018t Veer","year":"2002","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1126\/science.1132939","article-title":"The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease","volume":"313","author":"Lamb","year":"2006","journal-title":"Sci (n Y NY)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-025-02781-5","article-title":"High-throughput profiling of chemical-induced gene expression across 93,644 perturbations","volume":"22","author":"Xiang","year":"2025","journal-title":"Nat Methods"},{"key":"B15","doi-asserted-by":"publisher","first-page":"eabd7851","DOI":"10.1126\/sciadv.abd7851","article-title":"Tumor immunological phenotype signature-based high-throughput screening for the discovery of combination immunotherapy compounds","volume":"7","author":"Wang","year":"2021","journal-title":"Sci Adv"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1200305109","article-title":"Versatile pathway-centric approach based on high-throughput sequencing to anticancer drug discovery","volume":"109","author":"Li","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-018-0533-8","article-title":"Chemical genomics reveals inhibition of breast cancer lung metastasis by ponatinib via c-jun","volume":"10","author":"Shao","year":"2019","journal-title":"Protein Cell"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.scib.2021.01.005","article-title":"A large-scale transcriptional study reveals inhibition of COVID-19 related cytokine storm by traditional chinese medicines","volume":"66","author":"Dai","year":"2021","journal-title":"Sci Bull"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13184562","article-title":"PD-L1 dependent immunogenic landscape in hot lung adenocarcinomas identified by transcriptome analysis","volume":"13","author":"Kirfel","year":"2021","journal-title":"Cancers"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.955063","article-title":"Innate immune checkpoint inhibitor resistance is associated with melanoma sub-types exhibiting invasive and de-differentiated gene expression signatures","volume":"13","author":"Hossain","year":"2022","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.49","article-title":"Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy","volume":"17","author":"Nagarsheth","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0546-8","article-title":"Visualizing and interpreting cancer genomics data via the xena platform","volume":"38","author":"Goldman","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btz210","article-title":"TISIDB: an integrated repository portal for tumor-immune system interactions","volume":"35","author":"Ru","year":"2019","journal-title":"Bioinform (oxf Engl)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa407","article-title":"TIMER2.0 for analysis of tumor-infiltrating immune cells","volume":"48","author":"Li","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.862527","article-title":"Identification of a tumor immunological phenotype-related gene signature for predicting prognosis, immunotherapy efficacy, and drug candidates in hepatocellular carcinoma","volume":"13","author":"Tang","year":"2022","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/s13046-018-1002-1","article-title":"Classification of triple-negative breast cancers based on immunogenomic profiling","volume":"37","author":"He","year":"2018","journal-title":"J Exp Clin Cancer res: CR"},{"key":"B27","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/jcp.29842","article-title":"Exploration of the molecular characteristics of the tumor-immune interaction and the development of an individualized immune prognostic signature for neuroblastoma","volume":"236","author":"Jin","year":"2021","journal-title":"J Cell Physiol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.890150","article-title":"Immune-associated gene signatures serve as a promising biomarker of immunotherapeutic prognosis for renal clear cell carcinoma","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2021.06.024","article-title":"An immunogenomic signature for molecular classification in hepatocellular carcinoma","volume":"25","author":"Zhuang","year":"2021","journal-title":"Mol Ther Nucleic Acids"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygeno.2020.08.014","article-title":"A signature of immune-related gene pairs predicts oncologic outcomes and response to immunotherapy in lung adenocarcinoma","volume":"112","author":"Xu","year":"2020","journal-title":"Genomics"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100392","article-title":"Molecular predictors of response to pembrolizumab in thymic carcinoma","volume":"2","author":"He","year":"2021","journal-title":"Cell Rep Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"7015","DOI":"10.1038\/s41467-022-34676-w","article-title":"Elective nodal irradiation mitigates local and systemic immunity generated by combination radiation and immunotherapy in head and neck tumors","volume":"13","author":"Darragh","year":"2022","journal-title":"Nat Commun"},{"key":"B33","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","article-title":"Tumor and microenvironment evolution during immunotherapy with nivolumab","volume":"171","author":"Riaz","year":"2017","journal-title":"Cell"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-3556","article-title":"Immune-related gene expression profiling after PD-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma","volume":"77","author":"Prat","year":"2017","journal-title":"Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gks1193","article-title":"NCBI GEO: archive for functional genomics data sets\u2013update","volume":"41","author":"Barrett","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","article-title":"Defining a cancer dependency map","volume":"170","author":"Tsherniak","year":"2017","journal-title":"Cell"},{"key":"B37","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","article-title":"Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer","volume":"8","author":"Xue","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2022-0291","article-title":"Artificial intelligence in clinical applications for lung cancer: diagnosis, treatment and prognosis","volume":"60","author":"Pei","year":"2022","journal-title":"Clin Chem Lab Med"},{"key":"B39","volume-title":"Pharmacopoeia of the People\u2019s Republic of China","year":"2020"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.919940","article-title":"Nitidine chloride alleviates inflammation and cellular senescence in murine osteoarthritis through scavenging ROS","volume":"13","author":"Lin","year":"2022","journal-title":"Front Pharmacol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.12047\/j.cjap.5827.2019.115","article-title":"Effects of nitidine chloride on ulcerative colitis in mice and its mechanism","volume":"35","author":"Wu","year":"2019","journal-title":"Chin J Appl Physiol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104368","article-title":"Nitidine chloride exerts anti-inflammatory action by targeting topoisomerase I and enhancing IL-10 production","volume":"148","author":"Yang","year":"2019","journal-title":"Pharmacol Res"},{"key":"B43","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/s41419-019-1890-9","article-title":"High throughput circRNA sequencing analysis reveals novel insights into the mechanism of nitidine chloride against hepatocellular carcinoma","volume":"10","author":"Xiong","year":"2019","journal-title":"Cell Death Dis"},{"key":"B44","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3892\/ijmm.2013.1358","article-title":"Nitidine chloride inhibits hepatocellular carcinoma cell growth in vivo through the suppression of the JAK1\/STAT3 signaling pathway","volume":"32","author":"Liao","year":"2013","journal-title":"Int J Mol Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2018.4531","article-title":"DNA topoisomerase 1 and 2A function as oncogenes in liver cancer and May be direct targets of nitidine chloride","volume":"53","author":"Liu","year":"2018","journal-title":"Int J Oncol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"31618","DOI":"10.3892\/mmr.2016.4929","article-title":"Nitidine chloride inhibits ovarian cancer cell migration and invasion by suppressing MMP-2\/9 production via the ERK signaling pathway","volume":"13","author":"Sun","year":"2016","journal-title":"Mol Med Rep"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1080\/15384101.2017.1327490","article-title":"Nitidine chloride inhibited the expression of S phase kinase-associated protein 2 in ovarian cancer cells","volume":"16","author":"Mou","year":"2017","journal-title":"Cell Cycle (georget Tex),"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/jphp.12901","article-title":"Nitidine chloride inhibits proliferation and induces apoptosis in ovarian cancer cells by activating the fas signalling pathway","volume":"70","author":"Chen","year":"2018","journal-title":"J Pharm Pharmacol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13537","article-title":"Role of OCT2 and MATE1 in renal disposition and toxicity of nitidine chloride","volume":"173","author":"Li","year":"2016","journal-title":"Br J Pharmacol"},{"key":"B50","article-title":"Accumulation and mechanism of nitidine chloride in rat heart","volume":"54","author":"Li","year":"2019","journal-title":"Acta Pharmaceutica Sinica"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1676768\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T05:17:58Z","timestamp":1762751878000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1676768\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":50,"alternative-id":["10.3389\/fimmu.2025.1676768"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1676768","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"article-number":"1676768"}}